Yarrow Bioscience, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Yarrow Bioscience is in Stage 3, the topping phase, now in week 2 (since Oct 13, 2026). It closed at $19.60, 54.4% below its 52-week high and below its 200-day average, which is rising.

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. More about the company

$19.60

-2.83% today

$182M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is YARW early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 24w

S4 18w

S4 32w

S1 20w

S2 29w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 8w → S4 24w → S1 11w → S4 18w → S1 3w → S2 12w → S3 7w → S4 32w → S1 20w → S2 29w → S3 1w current

Total tracked: 166 weeks across 11 stage runs.

YARW among Biotechnology52nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…52	YARWYarrow Bioscience, Inc.	Stage 3 · wk 2	94	−29.7%

vs 52W High

-54.4%

$9.26 lo$42.94 hi

54.4% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-9.5%

200 DMA: $21.67 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.26x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.7%

-23.0%

+8.5%

YTD

+19.7%

+91.3%

Scan Membership

Breakout Watch

Latest: 2024-11-13

5 appearances in last 60 days. First seen: 2019-04-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 1.26x

2026-10-21S3

Wk 2 · Vol 0.60x

2026-10-20S3

Wk 2 · Vol 0.95x

2026-10-19S3

Wk 1 · Vol 2.01x

2026-10-16S3

Wk 1 · Vol 0.57x

2026-10-15S3

Wk 1 · Vol 1.78x

2026-10-14S3

Wk 1 · Vol 1.04x

2026-10-13S32→3

Wk 1 · Vol 1.00x

2026-10-12S2

Wk 28 · Vol 0.90x

2026-10-09S2

Wk 28 · Vol 1.69x

2026-10-08S2

Wk 28 · Vol 1.00x

2026-10-07S2

Wk 27 · Vol 1.53x

Moving averages & range

50 DMA

$28.14

200 DMA

$21.67

52W High

$42.94

52W Low

$9.26

5D Low

$18.31

Resistance levels (recent highs)

20d High

$25.54

60d High

$42.94

120d High

$42.94

250d High

$42.94

Next resistance

+30.3%

to 20d High

Dividend Yield

0.00%

P/B -0.8

Yarrow Bioscience: quick answers

What stage is Yarrow Bioscience in?

As of Oct 22, 2026, Yarrow Bioscience (YARW) is in Stage 3, the topping phase. It entered Stage 3 on Oct 13, 2026 and is in week 2. What the four stages mean

Is Yarrow Bioscience in an uptrend?

Its uptrend has stalled. Yarrow Bioscience is in Stage 3, the topping phase that follows an advance. It trades 9.5% below its 200-day average, which is rising.

How far is Yarrow Bioscience from its 52-week high?

Yarrow Bioscience closed at $19.60 on Oct 22, 2026, 54.4% below its 52-week high of $42.94. Its 52-week low is $9.26.

How has Yarrow Bioscience performed over the past year?

As of Oct 22, 2026, Yarrow Bioscience is up 91.3% over the past year and up 19.7% so far in 2026.

Which sector and industry is Yarrow Bioscience in?

Yarrow Bioscience is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.